Janux Therapeutics (JANX) Revenue (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Revenue data on file, last reported at $3.7 million in Q1 2026.

• Revenue for Q1 2026 came in at $3.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $13.7 million (up 47.1% YoY), and the FY2025 annual result was $10.0 million, down 5.55% from the prior year.
• Revenue eased to $3.7 million in Q1 2026 per JANX's latest filing, from $10.0 million in the prior quarter.
• Over five years, Revenue peaked at $10.0 million in Q3 2025 and troughed at $439000.0 in Q3 2024.
• A 5-year average of $3.2 million and a median of $2.4 million in 2022 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2025: Revenue slumped 82.56% in 2024, then jumped 2177.9% in 2025.
• A 5-year view of Revenue shows it stood at $2.8 million in 2022, then decreased by 13.5% to $2.5 million in 2023, then tumbled by 82.16% to $439000.0 in 2024, then jumped by 2177.9% to $10.0 million in 2025, then sank by 62.67% to $3.7 million in 2026.
• Business Quant data shows JANX's Revenue at $3.7 million in Q1 2026, $10.0 million in Q3 2025, and $439000.0 in Q3 2024.